Scientific Article
previous document  unige:29831  next document
add to browser collection

Efalizumab in the treatment of psoriasis

Published in Biologics. 2007, vol. 1, no. 3, p. 301-309
Abstract The humanized antibody efalizumab is currently the only T-cell directed biologic approved for the treatment of moderate-to-severe psoriasis by both American and European authorities. Binding to and blocking the function of the adhesion molecule leukocyte function associated antigen 1 (LFA-1), it is believed to interfere with T-cell activation in the lymph node, migration through the circulation into the skin, and re-activation in-loco, all of these representing central steps in the pathogenesis of psoriasis. A comprehensive clinical development program provided large and consistent evidence that efalizumab induces a major clinical benefit in psoriasis. Efalizumab rapidly and substantially improves psoriatic skin symptoms and leads to profound gain in quality of life. It allows safe and effective long-term control of psoriasis. Therefore, evidence-based treatment guidelines recommend its use in moderate to severe plaque-type psoriasis.
PMID: 19707339
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Other version:
(ISO format)
BOEHNCKE, Wolf-Henning. Efalizumab in the treatment of psoriasis. In: Biologics, 2007, vol. 1, n° 3, p. 301-309.

330 hits

0 download


Deposited on : 2013-09-20

Export document
Format :
Citation style :